469 related articles for article (PubMed ID: 25602521)
1. RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer.
Knudsen ES; McClendon AK; Franco J; Ertel A; Fortina P; Witkiewicz AK
Cell Cycle; 2015; 14(1):109-22. PubMed ID: 25602521
[TBL] [Abstract][Full Text] [Related]
2. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
[TBL] [Abstract][Full Text] [Related]
3. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.
Wang S; Liu JC; Kim D; Datti A; Zacksenhaus E
Breast Cancer Res; 2016 Jan; 18(1):9. PubMed ID: 26781438
[TBL] [Abstract][Full Text] [Related]
4. Modeling the effect of the RB tumor suppressor on disease progression: dependence on oncogene network and cellular context.
Dean JL; McClendon AK; Stengel KR; Knudsen ES
Oncogene; 2010 Jan; 29(1):68-80. PubMed ID: 19802012
[TBL] [Abstract][Full Text] [Related]
5. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.
Li M; Li A; Zhou S; Lv H; Yang W
J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840
[TBL] [Abstract][Full Text] [Related]
6. Generation of Osteosarcomas from a Combination of Rb Silencing and c-Myc Overexpression in Human Mesenchymal Stem Cells.
Wang JY; Wu PK; Chen PC; Lee CW; Chen WM; Hung SC
Stem Cells Transl Med; 2017 Feb; 6(2):512-526. PubMed ID: 28191765
[TBL] [Abstract][Full Text] [Related]
7. NUMB negatively regulates the epithelial-mesenchymal transition of triple-negative breast cancer by antagonizing Notch signaling.
Zhang J; Shao X; Sun H; Liu K; Ding Z; Chen J; Fang L; Su W; Hong Y; Li H; Li H
Oncotarget; 2016 Sep; 7(38):61036-61053. PubMed ID: 27506933
[TBL] [Abstract][Full Text] [Related]
8. Epithelial cell-derived periostin functions as a tumor suppressor in gastric cancer through stabilizing p53 and E-cadherin proteins via the Rb/E2F1/p14ARF/Mdm2 signaling pathway.
Lv H; Liu R; Fu J; Yang Q; Shi J; Chen P; Ji M; Shi B; Hou P
Cell Cycle; 2014; 13(18):2962-74. PubMed ID: 25486483
[TBL] [Abstract][Full Text] [Related]
9. RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation.
Jones RA; Robinson TJ; Liu JC; Shrestha M; Voisin V; Ju Y; Chung PE; Pellecchia G; Fell VL; Bae S; Muthuswamy L; Datti A; Egan SE; Jiang Z; Leone G; Bader GD; Schimmer A; Zacksenhaus E
J Clin Invest; 2016 Oct; 126(10):3739-3757. PubMed ID: 27571409
[TBL] [Abstract][Full Text] [Related]
10. Dual inactivation of RB and p53 pathways in RAS-induced melanomas.
Bardeesy N; Bastian BC; Hezel A; Pinkel D; DePinho RA; Chin L
Mol Cell Biol; 2001 Mar; 21(6):2144-53. PubMed ID: 11238948
[TBL] [Abstract][Full Text] [Related]
11. Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity.
Cicchini M; Chakrabarti R; Kongara S; Price S; Nahar R; Lozy F; Zhong H; Vazquez A; Kang Y; Karantza V
Autophagy; 2014; 10(11):2036-52. PubMed ID: 25483966
[TBL] [Abstract][Full Text] [Related]
12. RB1 and p53 at the crossroad of EMT and triple-negative breast cancer.
Jiang Z; Jones R; Liu JC; Deng T; Robinson T; Chung PE; Wang S; Herschkowitz JI; Egan SE; Perou CM; Zacksenhaus E
Cell Cycle; 2011 May; 10(10):1563-70. PubMed ID: 21502814
[TBL] [Abstract][Full Text] [Related]
13. Defining triple-negative breast cancer with neuroendocrine differentiation (TNBC-NED).
Hacking SM; Yakirevich E; Wang Y
J Pathol Clin Res; 2023 Jul; 9(4):313-321. PubMed ID: 37082801
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor-dependent cell cycle progression is altered in mammary epithelial cells that overexpress c-myc.
Nass SJ; Dickson RB
Clin Cancer Res; 1998 Jul; 4(7):1813-22. PubMed ID: 9676860
[TBL] [Abstract][Full Text] [Related]
15. Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status.
Jiang Z; Deng T; Jones R; Li H; Herschkowitz JI; Liu JC; Weigman VJ; Tsao MS; Lane TF; Perou CM; Zacksenhaus E
J Clin Invest; 2010 Sep; 120(9):3296-309. PubMed ID: 20679727
[TBL] [Abstract][Full Text] [Related]
16. Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.
Bennett CN; Tomlinson CC; Michalowski AM; Chu IM; Luger D; Mittereder LR; Aprelikova O; Shou J; Piwinica-Worms H; Caplen NJ; Hollingshead MG; Green JE
Breast Cancer Res; 2012 Jul; 14(4):R109. PubMed ID: 22812567
[TBL] [Abstract][Full Text] [Related]
17. A subgroup of microRNAs defines PTEN-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in RB1, MYC, and Wnt signaling.
Wang DY; Gendoo DMA; Ben-David Y; Woodgett JR; Zacksenhaus E
Breast Cancer Res; 2019 Jan; 21(1):18. PubMed ID: 30704524
[TBL] [Abstract][Full Text] [Related]
18. MiR-212-5p Suppresses the Epithelial-Mesenchymal Transition in Triple-Negative Breast Cancer by Targeting Prrx2.
Lv ZD; Yang DX; Liu XP; Jin LY; Wang XG; Yang ZC; Liu D; Zhao JJ; Kong B; Li FN; Wang HB
Cell Physiol Biochem; 2017; 44(5):1785-1795. PubMed ID: 29216628
[TBL] [Abstract][Full Text] [Related]
19. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
[TBL] [Abstract][Full Text] [Related]
20. p53 deficiency linked to B cell translocation gene 2 (BTG2) loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in patient-derived xenograft (PDX) models of triple-negative breast cancer.
Powell E; Shao J; Yuan Y; Chen HC; Cai S; Echeverria GV; Mistry N; Decker KF; Schlosberg C; Do KA; Edwards JR; Liang H; Piwnica-Worms D; Piwnica-Worms H
Breast Cancer Res; 2016 Jan; 18(1):13. PubMed ID: 26818199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
